Director Makes Bold Move with Major Stock Purchase in Zivo Bioscience!
Director Laith L. Yaldoo has purchased 1,659 shares of Zivo Bioscience, valued at $19,990, signaling confidence in the company. However, Spark's AI Analyst rates ZIVO as Underperform due to financial challenges, including negative equity and cash flow issues. The company has a year-to-date price performance of -36.52% and a market cap of $50.38M, indicating urgent need for financial restructuring.
Director Laith L. Yaldoo has made a significant investment in Zivo Bioscience by purchasing 1,659 shares of the company’s stock, valued at $19,990. This move indicates a strong vote of confidence in the company’s future prospects.
Spark’s Take on ZIVO Stock
According to Spark, TipRanks’ AI Analyst, ZIVO is a Underperform.
Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company’s negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.
To see Spark’s full report on ZIVO stock, click here.
More about Zivo Bioscience
YTD Price Performance: -36.52%
Average Trading Volume: 1,263
Technical Sentiment Signal: Sell
Current Market Cap: $50.38M
